联系客服

600535 沪市 天士力


首页 公告 600535:天士力关于公司2020年三季度主要经营数据的公告

600535:天士力关于公司2020年三季度主要经营数据的公告

公告日期:2020-10-29

600535:天士力关于公司2020年三季度主要经营数据的公告 PDF查看PDF原文

          证券代码:600535          证券简称:天士力        编号:临 2020-084 号

                      天士力医药集团股份有限公司

                关于公司 2020 年三季度主要经营数据的公告

              本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述

          或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。

              根据上海证券交易所发布的上市公司分行业信息披露指引《上市公司行业信

          息披露指引第七号——医药制造》及《关于做好上市公司 2020 年三季度报告披

          露工作的通知》相关要求,现将公司 2020 年三季度主要经营数据披露如下:

              一、报告期内分行业经营数据

                                                          单位:元币种:人民币

                  主营业务收入                          主营业务成本                  毛利率(%)

行业                                  增长                                  增长  2020  2019  增
      2020 年 1-9 月  2019 年 1-9 月  率(%) 2020 年 1-9 月  2019 年 1-9 月  率(%) 年 1-9  年 1-9  长
                                                                                      月    月    率

医药  4,480,982,913.29  4,572,590,422.72  -2.00  1,170,444,377.53  1,108,967,239.01    5.54  73.88  75.75  -1.87
工业

医药  6,811,505,175.79  9,467,298,609.99  -28.05  6,152,436,009.38  8,543,231,023.88  -27.98    9.68    9.76  -0.08
商业

合计  11,292,488,089.08  14,039,889,032.71  -19.57  7,322,880,386.91  9,652,198,262.89  -24.13  35.15  31.25  3.90

                                                          单位:元币种:人民币

      分治疗领域      营业收入        营业成本    毛利率  营业收入比  营业成本比上  毛利率比上

                                                    (%)  上年增减(%) 年增减(%)  年增减(%)

      心脑血管    2,803,483,135.63    738,442,174.85    73.66        -12.21            0.40      -3.31

        抗肿瘤        630,437,585.79    84,417,408.34    86.61        -5.80          -37.80      6.89

      感冒发烧      271,472,511.99    141,682,821.02    47.81        168.29          198.88      -5.34

      肝病治疗      325,710,649.81    58,828,387.98    81.94        34.86          14.45      3.22

        其他        449,879,030.07    147,073,585.34    67.31        22.50            5.83      5.15

    医药工业小计  4,480,982,913.29  1,170,444,377.53    73.88        -2.00            5.54      -1.87


  分治疗领域      营业收入        营业成本    毛利率  营业收入比  营业成本比上  毛利率比上

                                                (%)  上年增减(%) 年增减(%)  年增减(%)

 医药商业小计  6,811,505,175.79  6,152,436,009.38      9.68        -28.05          -27.98      -0.08

    合计      11,292,488,089.08  7,322,880,386.91    35.15        -19.57          -24.13      3.90

                                                      单位:元币种:人民币

  分产品        营业收入        营业成本      毛利率  营业收入比上  营业成本比上  毛利率比上
                                                (%)    年增减(%)  年增减(%)  年增减(%)

  中药        3,055,385,345.19    887,724,648.14    70.95          -4.09          10.51        -3.84

 化学制剂药    1,249,915,275.84    195,301,083.88    84.37            8.63          -18.39        5.17

 化学原料药      45,830,816.48      23,971,412.20    47.70          31.57          10.01        10.25

  生物药        129,851,475.78      63,447,233.31    51.14          -35.57          42.36      -26.75

医药工业小计  4,480,982,913.29    1,170,444,377.53    73.88          -2.00            5.54        -1.87

医药商业小计  6,811,505,175.79    6,152,436,009.38      9.68          -28.05          -27.98        -0.08

  合计      11,292,488,089.08    7,322,880,386.91    35.15          -19.57          -24.13        3.90

              报告期内,公司受到疫情以及三个医保谈判品种执行新价格的影响,感

          冒发烧药品销售收入较去年同期有大幅增长,心脑血管和抗肿瘤产品收入同

          比下降。

              公司生物药普佑克 2020 年 1 至 9 月销量较去年同期增长 58.10%,因执行

          新的医保谈判价格并对渠道库存价格补差导致 1 至 9 月收入较去年同期下降

          35.57%。

              二、报告期内分地区经营数据

                                                      单位:元币种:人民币

            地区    本期累计主营业务收入  上年同期累计主营业务收入  增长比例(%)

          天津市            7,554,470,937.67              8,056,781,393.56            -6.23

          陕西省            2,656,168,534.22              3,692,972,145.50          -28.08

          辽宁省            1,607,494,495.36              2,050,590,463.05          -21.61

          山西省            1,076,047,684.46              1,263,692,844.40          -14.85

          江苏省            1,034,944,131.52              981,406,022.09            5.46


 地区    本期累计主营业务收入  上年同期累计主营业务收入  增长比例(%)

 湖南省            571,897,397.74              897,992,718.17          -36.31

 广东省            555,418,911.20              849,776,948.60          -34.64

 北京市            292,522,479.21              593,883,327.91          -50.74

 山东省            284,902,427.97              340,895,335.23          -16.43

 上海市            130,066,372.52              201,489,687.81          -35.45

 其他              88,120,245.79              173,233,348.83          -49.13

 小计            15,852,053,617.66            19,102,714,235.15          -17.02

 抵消            4,559,565,528.58              5,062,825,202.44            -9.94

 合并            11,292,488,089.08            14,039,889,032.71          -19.57

    注:上表中地区分布以公司所在地划分。

    报告期内上海市销售收入同比下降主要系普佑克降价所致;其他地区销售收入同比下降主
[点击查看PDF原文]